BenevolentAI Investor Presentation Deck
Pipeline depth and progression
Disease Area
BEN2293 | Atopic Dermatitis (PanTrk inhibitor)
BEN8744 | Ulcerative Colitis (PDE10 Inhibitor)
BEN9160 | Amyotrophic Lateral Sclerosis
Glioblastoma Multiforme
Inflammatory Bowel Diseases
CNS Diseases
Antiviral
Nonalcoholic Steatohepatitis (NASH)
Oncology
Nonalcoholic Steatohepatitis (NASH)
Oncology
Oncology
Parkinson's Disease
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
10+ Early Discovery Programmes
(Multiple indications & targets in therapy
Source: (1) GlobalData, Epidemiology forecasts 2021, Atopic Dermatitis (7MM), IBD (8MM),
ALS (8MM), GBM (7MM), NASH (7MM), CKD (7MM), IPF (7MM); 7MM = 7 major markets (US,
JP, EU5); 8MM = US, JP, EU5+ Canada; (2) Evaluate Pharma, Current Worldwide Market Size
(data pull 22nd Sept 2021) Atopic Dermatitis, IBD, ALS, GBM, NASH, CKD, IPF
Target ID
Hit to Lead
AstraZeneca
AstraZeneca
AstraZeneca
Lead Opt
Preclinical
Phase I start
in early 2023
Clinical
Commercial
Highlights
• All Pipeline programmes
generated from Benevolent
Platform™
• Broad therapy area coverage
given disease agnostic
approach
• Mix of Best in class, First in
class and novel indications
• Potential for rapid scaling and
expansion into new modalities
Benevolent
9View entire presentation